New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
06:18 EDTBOTABiota Pharmaceuticals downgraded to Neutral from Buy at Guggenheim
News For BOTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2015
09:28 EDTBOTABiota Pharmaceuticals commences dosing of BTA585 Phase 1 trial
Biota Pharmaceuticals announced that it has commenced dosing in a 50-subject, randomized, placebo-controlled, Phase 1 single ascending dose, or SAD, trial to evaluate the safety and pharmacokinetics, or PK, of BTA585 in healthy volunteers. BTA585, a potent inhibitor of viral entry into cells, is an orally bioavailable compound in clinical development for the treatment of respiratory syncytial virus, RSV, infections in children, the elderly and immunocompromised patients.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use